Wednesday, September 14, 2011

Whytorin contd. - GBA to decide on future of Merck's ezetimibe after German assessment sees no benefit

IQWiG, Germany's Institute for Quality and Efficacy in Healthcare, says that the benefits of the hypolipidaemic combination product ezetimibe are not clear. The institute's report does not bode well for Merck & Co, which markets Zetia (ezetimibe) and Vytorin (ezetimibe plus simvastatin).


http://www.scripintelligence.com/home/GBA-to-decide-on-future-of-Mercks-ezetimibe-after-German-assessment-sees-no-benefit-321152?

No comments: